NextCure (NXTC) announced a merger agreement with Avere Therapeutics on July 14, 2026. NextCure will acquire Avere through a two-step merger, issuing shares of NextCure common stock to Avere stockholders. After the merger, former Avere stockholders are expected to own about 98.11% of the combined company, while current NextCure stockholders will hold only about 1.89%. The agreement also includes accelerated vesting of equity awards and cash payouts for some stock options.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding NEXTCURE INC (NXTC)?

Major stakeholders currently include Squadron Capital Management LLC ($2.8M), Affinity Asset Advisors, LLC ($2.6M), Ikarian Capital, LLC ($2.5M). Based on the latest 13F filings, there are a total of 24 tracked investment funds and institutions maintaining positions in NXTC.

What is the overall institutional sentiment toward NXTC recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $5.8M, driven by 8 managers accumulating shares while 8 reduced their exposure.

Which institutions have been selling or reducing their NXTC positions?

In the latest period, 4 funds trimmed their holdings, and 4 managers completely exited their positions. The aggregate reported sell value was $9.0M.

Are there any notable investors adding NXTC to their portfolios?

Yes, buying activity remains notable. 5 institutions opened new positions in {ticker}, and 3 existing holders added to their shares. The total reported buy value for the quarter amounted to $6.2M.